Glaukos Q2 Earnings Beat Estimates on iDose TR Growth, Stock Up
Glaukos (GKOS) reported Q2 2026 adjusted loss of 14 cents per share, better than the Zacks Consensus loss of 28 cents. Revenue rose to $185.6 million, up 50% year over year, beating the consensus by 24.1%. Management raised 2026 net sales guidance to $680 million to $700 million. Shares rose 9.8% in after-hours.
How this was made
The 30-second read
Why it matters
This is a classic earnings-and-guidance repricing setup: the company beat on revenue, narrowed losses, and raised 2026 net sales guidance, which can shift valuation multiples and near-term positioning.
Market read
Traders get a fresh decision set from the combination of earnings beat, after-hours stock reaction, and explicit upward guidance for 2026 net sales.
What to watch
The article highlights expense growth (SG&A and R&D up sharply). If operating leverage does not continue, the margin expansion narrative could fade despite the top-line beat.
Background
Glaukos is a glaucoma-focused medtech company with iDose TR adoption as a key growth driver and Epioxa commercialization progressing via reimbursement and site-of-care expansion.
Ticker impact
Glaukos reported Q2 results with a narrower adjusted loss, revenue beat, and raised full-year 2026 revenue guidance, sending shares up ~9.8% after hours.
Bullish bias for the next session(s) as traders reprice 2026 net sales toward the raised $680M to $700M range.
The article discloses multiple decision-relevant datapoints: adjusted loss improvement vs consensus, revenue outperformance, and explicit upward guidance with a quantified range.
Market effects
Reinforces investor appetite for glaucoma medtech names tied to procedure adoption and reimbursement progress, potentially lifting sentiment across ophthalmology peers.
Limited direct regional read-through; growth is described as U.S. and international, but no country-specific regulatory shocks are cited.
International revenue growth and global commercial infrastructure expansion may modestly support broader medtech risk-on positioning.
Counterpoint
The guidance raise may already be partially priced given the large after-hours move; investors may focus on whether iDose TR adoption and Epioxa ramp can sustain the implied growth rate.
Key entities
- companyGlaukos Corporation
Reported Q2 2026 adjusted loss of 14 cents per share, revenue of $185.6M, and raised 2026 net sales guidance to $680M-$700M.
- productiDose TR
Adoption and utilization growth drove Q2 revenue strength and underpins the raised full-year outlook.
- productEpioxa
Commercial launch progress includes a J-code effective July 1, 2026 and a co-pay assistance program, supporting second-half reimbursement streamlining.
